HCmed UK is pleased to announce the appointment of Chris Vernall as its new Executive Vice President (EVP) of Business Development. In this role, Chris will help facilitate new business, foster cross-industry collaborations, and provide strategic support for the company’s commercial activities.

Chris brings extensive expertise in respiratory drug product development and a strong commercial background, having held key leadership positions at Intertek, Nanopharm, and Vectura. With over 15 years' experience in the pharmaceutical and healthcare sectors, he has been instrumental in driving innovation, managing strategic partnerships, and supporting the development of advanced inhalation therapies.

Chris holds a Master’s degree in Chemistry from Loughborough University and a Master’s in Executive Leadership from Imperial College Business School. He has recently served as Co-Chair of the IPAC-RS Inhaled and Nasal Biologics Steering Committee and was also one of the founders of the annual Inhaled and Nasal Biologics Forum. His deep understanding of respiratory drug development, coupled with his commercial expertise, makes him a valuable addition to HCmed Innovations as the company continues to expand its global reach and network of partners.